Parse Biosciences Launches Trailmaker Data Analysis Platform to Simplify Single Cell Sequencing
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Trailmaker™, its user-friendly cloud platform purpose-built for single cell data analysis. Fast, scalable, and capable of providing end-to-end analysis, Trailmaker removes common analysis barriers, rapidly transforming single cell data into biological insights.
Single-cell RNA sequencing (scRNA-seq) offers researchers comprehensive insights into biological systems and finds applications in diverse fields such as developmental biology, oncology, and immunology. As scRNA-seq becomes more widely adopted and experiment sizes scale, there is a growing need for accessible data analysis methods that help researchers easily generate biological insights.
"Traditional single cell data analysis presents a number of challenges, including data processing, visualization, data integration and interpretation, as well as a shortage of experts who can process the data," noted Parse Biosciences co-founder and CTO Charlie Roco. "Our goal is to make single cell research easier, more cost effective, and more scalable. With Trailmaker, any scientist can easily process and analyze their single cell data, enabling them to draw insights from their experiments and projects more quickly."
Trailmaker can take unprocessed sequencing files (FASTQ) generated from Evercode Whole Transcriptome kits and provide downstream data visualizations and publication-ready figures in a few simple clicks, without the need for a single line of code.
The new platform is a direct result of Parse Biosciences’ acquisition of Biomage in early 2024. Already in use by over 4,500 researchers, the rebranded and enhanced data analysis platform is now officially available to Parse Biosciences’ customers and all academic researchers free of charge.
Parse Biosciences will be discussing the capabilities of Trailmaker at this year’s European Society of Human Genetics Meeting in Berlin, Germany, June 1-5.
About Parse Biosciences
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach is enabling groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
Founded based on a transformative technology invented at the University of Washington, Parse has raised over $100 million and is used in nearly 2,000 labs across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Capture, and a software tool for data analysis.
Headquartered in Seattle, Washington’s vibrant South Lake Union district, Parse Biosciences recently opened a 34,000 square foot headquarters and state-of-the-art laboratory.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530324847/en/
Contact information
Jay Roberts, SRPR
jay@shevrushpr.com | 917.696.2142
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge ® (omidubicel-onlv)11.3.2025 12:00:00 CET | Press Release
Ayrmid Pharma Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics and RoslinCT, a world leading cell and gene therapy contract development and manufacturing organization (CDMO), today announced their intent to enter into a strategic partnership for the production of Omisirge, a commercial product for the treatment of hematologic malignancies commercialized in the US by Gamida Cell Inc, a subsidiary of Ayrmid Pharma Ltd. It is the intent of the two companies to enter into an agreement whereby RoslinCT will perform technology transfer and commercial manufacture of Gamida Cell’s Omisirge. The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA approved and launched in 2023. It is the intent of the two companies that the technology transfer and commercial manufacturing will take place in RoslinCT's state-of-the-art, purpose-built cell therapy CGMP manufacturing facility in Hopkinton, MA. “As part of our globa
Kinaxis to Unveil the Next Phase of AI Innovation at Kinexions 202511.3.2025 12:00:00 CET | Press Release
Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, is set to unveil new artificial intelligence capabilities in its Maestro™ platform at Kinexions North America 2025, the company’s global innovation conference. These AI capabilities are designed to accelerate the value that AI can create in supply chains, helping companies navigate an increasingly volatile global trade environment - whether they are just beginning their AI journey or already leveraging advanced automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250311610609/en/ The company will introduce AI agents that users can interact with to monitor, predict, and take action in real time — automating key tasks like inventory management and disruption mitigation. In addition, its agentic AI framework will enable companies to easily create their own AI agents on Maestro, making AI-driven supply chain orchestration accessible to businesses
Verne Strikes 10MW Deal with Nebius to Further Expand Europe’s AI Capacity11.3.2025 11:00:00 CET | Press Release
Verne, the leading provider of sustainably powered HPC data centers across the Nordics, has today announced that Nebius, a leading global AI infrastructure provider, will be colocating a cluster of NVIDIA H200 GPUs at Verne’s data center campus in Iceland. This collaboration marks the largest single implementation in Verne Iceland’s history, with Nebius deploying a 10MW cluster. This installation is part of Nebius’ ambitious build-out of AI infrastructure across the US and Europe, supporting its mission to provide scalable, energy-efficient solutions for intensive AI workloads. As one of Europe’s leading providers of GPU capacity, Nebius selected Verne for its proven expertise, renewable energy-driven operations, and ability to meet precise technical and geographical requirements. Verne’s Icelandic facility, uniquely located on a former NATO base and powered entirely by Iceland’s 100% renewable hydroelectric and geothermal energy resources, aligns perfectly with Nebius’ approach to ado
Allegro DVT Launches its First AI-Based Neural Video Processing IP11.3.2025 10:35:00 CET | Press Release
Allegro DVT, a leader in video processing semiconductor solutions, is excited to announce the launch of its latest innovation, its first AI-based Neural Video Processing NVP300 IP. This groundbreaking product marks Allegro DVT’s commitment to embrace the AI revolution and push video quality to the next level, leveraging the advanced features and benefits of AI based video processing technologies. The new NVP300 semiconductor IP features an optimized hardware implementation to deliver real-time AI processing of 4K video within best-in-class silicon area and power budget suitable for embedded products. "We are thrilled to introduce our first AI-based Neural Video Processing IP to the market," said Nouar Hamze, CEO at Allegro DVT. "The NVP300 represents a significant advancement in video processing technology offering stunning subjective video quality improvements. It will greatly benefit our customers to power their next generation video compression solutions." The launch of the AI-based
Interactive Brokers Expands Global Reach with Ljubljana Stock Exchange Access11.3.2025 10:00:00 CET | Press Release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced today that it has expanded its market offerings by adding access to the Ljubljana Stock Exchange. With this expansion, clients can trade Slovenian equities alongside products from over 160 other global exchanges, including stocks, options, futures, currencies, bonds, funds, and more, from a single unified platform. Enhancing Market Access for Global Investors Interactive Brokers provides access to over 160 markets across the Americas, Europe, and Asia, and adding the Ljubljana Stock Exchange further broadens the investment opportunities for our active traders and institutional investors. Clients can now include Slovenian stocks as part of their portfolio diversification strategies, complementing their European and global investments. "Interactive Brokers continues to expand its market coverage to meet the needs of global investors," said Milan Galik, Chief Executive Officer of Interactive Brokers. "Add
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom